FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000456517> ?p ?o ?g. }

• W2000456517 abstract "Background The morbidity and treatment costs associated with skin and soft tissue infections (SSTIs) are high. Linezolid and vancomycin are antibiotics that are commonly used in treating skin and soft‐tissue infections, specifically those infections due to methicillin‐resistant Staphylococcus aureus (MRSA). Objectives To compare the effects and safety of linezolid and vancomycin for treating people with SSTIs. Search methods For this first update of this review we conducted searches of the following databases: Cochrane Wounds Group Specialised Register (searched 24 March 2015; The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In‐Process & Other Non‐Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. We also contacted manufacturers for details of unpublished and ongoing trials. We scrutinised citations within all obtained trials and major review articles to identify any additional trials. Selection criteria We included all randomised controlled trials (RCTs) comparing linezolid with vancomycin in the treatment of SSTIs. Data collection and analysis Two review authors independently selected trials, assessed risk of bias and extracted data. The primary outcomes were clinical cure, microbiological cure, and SSTI‐related and treatment‐related mortality. We performed subgroup analyses according to age, and whether the infection was due to MRSA. Main results No new trials were identified for this first update. We included nine RCTs (3144 participants). Linezolid was associated with a significantly better clinical (RR 1.09, 95% CI 1.03 to 1.16) and microbiological cure rate in adults (RR 1.08, 95% CI 1.01 to 1.16). For those infections due to MRSA, linezolid was significantly more effective than vancomycin in clinical (RR 1.09, 95% CI 1.03 to 1.17) and microbiological cure rates (RR 1.17, 95% CI 1.04 to 1.32). No RCT reported SSTI‐related and treatment‐related mortality. There was no significant difference in all‐cause mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80). There were fewer incidents of red man syndrome (RR 0.04, 95% CI 0.01 to 0.29), pruritus (RR 0.36, 95% CI 0.17 to 0.75) and rash (RR 0.27, 95% CI 0.12 to 0.58) in the linezolid group compared with vancomycin, however, more people reported thrombocytopenia (RR 13.06, 95% CI 1.72 to 99.22), and nausea (RR 2.45, 95% CI 1.52 to 3.94) when treated with linezolid. It seems, from the available data, that length of stay in hospital was shorter for those in the linezolid group than the vancomycin group. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin. Although inpatient treatment with linezolid cost more than inpatient treatment with vancomycin per day, the median length of hospital stay was three days shorter with linezolid. Thus, total hospital charges per patient were less with linezolid treatment than with vancomycin treatment. Authors' conclusions Linezolid seems to be more effective than vancomycin for treating people with SSTIs, including SSTIs caused by MRSA. The available evidence is at high risk of bias and is based on studies that were supported by the pharmaceutical company that makes linezolid. Further well‐designed, independently‐funded, RCTs are needed to confirm the available evidence." @default.
• W2000456517 created "2016-06-24" @default.
• W2000456517 creator A5002698291 @default.
• W2000456517 creator A5005584314 @default.
• W2000456517 creator A5023307603 @default.
• W2000456517 creator A5028216952 @default.
• W2000456517 creator A5064683226 @default.
• W2000456517 creator A5089024368 @default.
• W2000456517 date "2016-01-07" @default.
• W2000456517 modified "2023-10-14" @default.
• W2000456517 title "Linezolid versus vancomycin for skin and soft tissue infections" @default.
• W2000456517 cites W102809629 @default.
• W2000456517 cites W1555403508 @default.
• W2000456517 cites W1602750988 @default.
• W2000456517 cites W1964500513 @default.
• W2000456517 cites W1965705252 @default.
• W2000456517 cites W1967036482 @default.
• W2000456517 cites W1972703554 @default.
• W2000456517 cites W1973427448 @default.
• W2000456517 cites W1975850307 @default.
• W2000456517 cites W1983151053 @default.
• W2000456517 cites W1985184557 @default.
• W2000456517 cites W1987653198 @default.
• W2000456517 cites W1987977747 @default.
• W2000456517 cites W1990570490 @default.
• W2000456517 cites W1991605947 @default.
• W2000456517 cites W1993119474 @default.
• W2000456517 cites W1996738507 @default.
• W2000456517 cites W2001604291 @default.
• W2000456517 cites W2002188750 @default.
• W2000456517 cites W2003951775 @default.
• W2000456517 cites W2011932878 @default.
• W2000456517 cites W2019324782 @default.
• W2000456517 cites W2019351961 @default.
• W2000456517 cites W2021660575 @default.
• W2000456517 cites W2031069021 @default.
• W2000456517 cites W2035194773 @default.
• W2000456517 cites W2038795749 @default.
• W2000456517 cites W2045768636 @default.
• W2000456517 cites W2046700614 @default.
• W2000456517 cites W2053980008 @default.
• W2000456517 cites W2056026648 @default.
• W2000456517 cites W2063380036 @default.
• W2000456517 cites W2064223985 @default.
• W2000456517 cites W2065917614 @default.
• W2000456517 cites W2090505190 @default.
• W2000456517 cites W2090874066 @default.
• W2000456517 cites W2091382682 @default.
• W2000456517 cites W2092196558 @default.
• W2000456517 cites W2100886773 @default.
• W2000456517 cites W2101952910 @default.
• W2000456517 cites W2108455533 @default.
• W2000456517 cites W2110055188 @default.
• W2000456517 cites W2111939960 @default.
• W2000456517 cites W2114448040 @default.
• W2000456517 cites W2115213265 @default.
• W2000456517 cites W2121922598 @default.
• W2000456517 cites W2125435699 @default.
• W2000456517 cites W2125675160 @default.
• W2000456517 cites W2132250711 @default.
• W2000456517 cites W2135596283 @default.
• W2000456517 cites W2139745528 @default.
• W2000456517 cites W2148440281 @default.
• W2000456517 cites W2149993789 @default.
• W2000456517 cites W2152652294 @default.
• W2000456517 cites W2164551028 @default.
• W2000456517 cites W2169530071 @default.
• W2000456517 cites W2276443311 @default.
• W2000456517 cites W326534605 @default.
• W2000456517 cites W4214559180 @default.
• W2000456517 cites W4297776343 @default.
• W2000456517 doi "https://doi.org/10.1002/14651858.cd008056.pub3" @default.
• W2000456517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26758498" @default.
• W2000456517 hasPublicationYear "2016" @default.
• W2000456517 type Work @default.
• W2000456517 sameAs 2000456517 @default.
• W2000456517 citedByCount "38" @default.
• W2000456517 countsByYear W20004565172013 @default.
• W2000456517 countsByYear W20004565172014 @default.
• W2000456517 countsByYear W20004565172016 @default.
• W2000456517 countsByYear W20004565172017 @default.
• W2000456517 countsByYear W20004565172018 @default.
• W2000456517 countsByYear W20004565172019 @default.
• W2000456517 countsByYear W20004565172020 @default.
• W2000456517 countsByYear W20004565172021 @default.
• W2000456517 countsByYear W20004565172022 @default.
• W2000456517 countsByYear W20004565172023 @default.
• W2000456517 crossrefType "journal-article" @default.
• W2000456517 hasAuthorship W2000456517A5002698291 @default.
• W2000456517 hasAuthorship W2000456517A5005584314 @default.
• W2000456517 hasAuthorship W2000456517A5023307603 @default.
• W2000456517 hasAuthorship W2000456517A5028216952 @default.
• W2000456517 hasAuthorship W2000456517A5064683226 @default.
• W2000456517 hasAuthorship W2000456517A5089024368 @default.
• W2000456517 hasConcept C126322002 @default.
• W2000456517 hasConcept C141071460 @default.
• W2000456517 hasConcept C168563851 @default.
• W2000456517 hasConcept C17744445 @default.
• W2000456517 hasConcept C177713679 @default.
• W2000456517 hasConcept C199539241 @default.

• next